Preoperative Plasma Levels of Transforming Growth Factor Beta1 (TGF-β1) Strongly Predict Progression in Patients Undergoing Radical Prostatectomy
- 1 June 2001
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 19 (11) , 2856-2864
Abstract
PURPOSE: Elevated local and circulating levels of transforming growth factor beta1 (TGF-β1) have been associated with prostate cancer invasion and metastasis. We tested the hypothesis that preoperative plasma TGF-β1 levels would independently predict cancer stage and prognosis in patients who undergo radical prostatectomy. PATIENTS AND METHODS: The study group consisted of 120 consecutive patients who underwent radical prostatectomy for clinically localized prostate cancer (median follow-up, 53.8 months). Preoperative plasma levels of TGF-β1 were measured and correlated with pathologic parameters and clinical outcomes. TGF-β1 levels also were measured in 44 healthy men without cancer, in 19 men with prostate cancer metastatic to regional lymph nodes, and in 10 men with prostate cancer metastatic to bone. RESULTS: Plasma TGF-β1 levels in patients with lymph node metastases (14.2 ± 2.6 ng/mL) and bone metastases (15.5 ± 2.4 ng/mL) were higher than those in radical prostatectomy patients (5.2 ± 1.3 ng/mL) and healthy subjects (4.5 ± 1.2 ng/mL) (P < .001). In a preoperative analysis, preoperative plasma TGF-β1 level and biopsy Gleason sum both were predictors of organ-confined disease (P = .006 and P = .006, respectively) and PSA progression (P < .001 and P = .021, respectively). In a postoperative multivariate analysis, preoperative plasma TGF-β1 level, pathologic Gleason sum, and surgical margin status were predictors of PSA progression (P = .020,P = .020, and P = .022, respectively). In patients who progressed, preoperative plasma TGF-β1 levels were higher in those with presumed distant compared with local-only failure (P = .019). CONCLUSION: Plasma TGF-β1 levels are markedly elevated in men with prostate cancer metastatic to regional lymph nodes and bone. In men without clinical or pathologic evidence of metastases, the preoperative plasma TGF-β1 level is a strong predictor of biochemical progression after surgery, presumably because of an association with occult metastatic disease present at the time of radical prostatectomy.Keywords
This publication has 44 references indexed in Scilit:
- PREOPERATIVE SERUM PROSTATE SPECIFIC ANTIGEN DOES NOT REFLECT BIOCHEMICAL FAILURE RATES AFTER RADICAL PROSTATECTOMY IN MEN WITH LARGE VOLUME CANCERSJournal of Urology, 2000
- TRENDS IN MORTALITY RATES IN PATIENTS WITH PROSTATE CANCER DURING THE ERA OF PROSTATE SPECIFIC ANTIGEN SCREENINGJournal of Urology, 2000
- Radical Prostatectomy: Does Higher Volume Lead to Better Quality?JNCI: Journal of the National Cancer Institute, 1999
- Plasma transforming growth factor-?1 level before radiotherapy correlates with long term outcome of patients with lung carcinomaCancer, 1999
- THE INFLUENCE OF PATHOLOGICAL PARAMETERS OF POSITIVE SURGICAL MARGINS ON PROGNOSIS IN PATIENTS UNDERGOING RADICAL PROSTATECTOMYJournal of Urology, 1999
- ELEVATED LEVELS OF CIRCULATING INTERLEUKIN-6 AND TRANSFORMING GROWTH FACTOR-beta 1 IN PATIENTS WITH METASTATIC PROSTATIC CARCINOMAJournal of Urology, 1999
- Transforming Growth Factor Beta 1 is Significantly Elevated in Plasma of Patients Suffering from Renal Cell CarcinomaCytokine, 1996
- Observations on the doubling time of prostate cancer.The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volumeCancer, 1993
- Transforming growth factor β1 as a biomarker for prostate cancerJournal of Cellular Biochemistry, 1992
- Production and significance of TGF-β in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinomaBiochemical and Biophysical Research Communications, 1990